Identifying genetic and environmental factors in multiple sclerosis
Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility
This study is trying to find out how genes and the environment might increase the risk of developing multiple sclerosis by gathering information from 5,000 people who are at risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Columbia University Academic / other |
| Locations | 5 sites (Bethesda, Maryland and 4 other locations) |
| Trial ID | NCT01353547 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify the genetic, environmental, and immune profiles that may increase the risk of developing multiple sclerosis (MS). By enrolling 5000 subjects who are at risk, the study will collect biological specimens and conduct online surveys to gather comprehensive data. The goal is to understand the interplay of genetic alterations, environmental exposures, and immune factors in the onset of MS, which could lead to effective prevention strategies in the future.
Who should consider this trial
Good fit: Ideal candidates include first-degree relatives of MS patients, individuals who have received anti-TNFa therapy for other inflammatory diseases, or those referred for evaluation of neurological symptoms without a diagnosis of MS.
Not a fit: Patients who do not meet the inclusion criteria will not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved prevention and management strategies for individuals at risk of developing multiple sclerosis.
How similar studies have performed: Other studies have shown success in identifying risk factors for autoimmune diseases, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * First Degree Relatives of Patients with MS, or * Patients who have received anti-TNFa therapy as treatment for inflammatory diseases other than MS such as Crohn's disease, psoriasis and rheumatoid arthritis, or * Patients that have been referred for an evaluation of first presentation of neurologic symptoms but do not have a diagnosis of MS * Live in the United States Exclusion Criteria: * Does not match any of the inclusion criteria
Where this trial is running
Bethesda, Maryland and 4 other locations
- National Institute of Neurological Disorders and Stroke — Bethesda, Maryland, United States (Recruiting)
- Massachusetts General Hospital — Boston, Massachusetts, United States (Terminated)
- Brigham and Women's Hospital — Boston, Massachusetts, United States (Terminated)
- Columbia University Irving Center — New York, New York, United States (Recruiting)
- University of Pittsburgh — Pittsburgh, Pennsylvania, United States (Recruiting)
Study contacts
- Study coordinator: Juliana Oyegunle
- Email: jbo2120@cumc.columbia.edu
- Phone: 212-305-2434
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.